Amplifica Raises $26 Million With Eli Lilly While PP405 Hype Faces a Data Reality Check

On August 12, 2026, Amplifica announced an oversubscribed $26 million Series B to push its injectable hair-growth pipeline further into clinical development. Tasso Partners led the round. Eli Lilly and Company participated alongside principals of Scopia Capital Management and other new and existing investors.¹

The Eli Lilly name will drive the headlines, and fairly so. A major pharmaceutical company placing money into a small private hair-regeneration company makes Amplifica harder to dismiss as an academic science project. The better signal, though, is the combination of new capital, multiple programs, and an early human result that was strong enough to justify another development cycle.¹⁴

Lilly's presence is also bigger than one company. A June 2026 SEC prospectus allocated $40 million of Absci's $100 million stock offering to Lilly. Absci said those proceeds would help advance ABS-201, its injectable anti-prolactin-receptor antibody for pattern hair loss and endometriosis. Lilly now has financial exposure to more than one experimental hair-growth strategy. That makes the category look increasingly serious, but it also means the Amplifica investment should not be mistaken for Lilly choosing a winner.²

It is still financing, not an efficacy endpoint. Investors can be wrong, strategic investments can be exploratory, and the release does not disclose Lilly's check size or any development partnership. The round buys Amplifica the chance to generate better evidence. It does not substitute for that evidence.¹

Amplifica is a San Diego clinical-stage biotechnology company built around a simple observation: follicles that look dormant can still respond when the local biological signals are right. Its public pipeline is not another minoxidil brand or a single daily topical. It is a group of injectable programs intended to stimulate follicle activity through different mechanisms.³⁴

The scientific identity comes largely from co-founder and chief scientific officer Maksim Plikus, a University of California, Irvine professor whose laboratory studies how skin cells and the hair-follicle niche coordinate regeneration. His group helped identify osteopontin and SCUBE3 as growth-promoting signals in experimental systems. Amplifica also lists AMP-303, AMP-203 and AMP-506 alongside AMP-601 on its current pipeline page.⁴⁸¹⁰

That breadth is Amplifica's strongest strategic argument. Hair cycling is not controlled by one switch. A company pursuing several signaling routes has more ways to learn, combine programs, or move on if one mechanism disappoints. It also has more programs to fund, manufacture, inject, and validate. Breadth raises the ceiling and the execution burden at the same time.

A surprising amount of coverage collapses Amplifica's entire origin story into one sentence: AMP-303 is osteopontin. The primary record does not support that shortcut. The 2025 clinical abstract describes AMP-303 as a novel polysaccharide. An Amplifica patent tied to the same split-scalp study explicitly describes AMP-303 as non-crosslinked, low-molecular-weight hyaluronic acid in phosphate-buffered saline, with hyaluronic acid acting as the active ingredient as well as the carrier.⁵⁷

The patent proposes a CD44-based rationale. Hyaluronic acid is a natural CD44 ligand, and the application says the selected molecular-weight range is intended to provoke a controlled hair-growth signal without unacceptable inflammation. Its worked example matches the public study closely: frontotemporal injections, recent and long-standing hair-loss cohorts, a contralateral saline control, and follow-up through roughly five months.⁷

A patent can describe multiple embodiments and does not guarantee that every future clinical lot will remain unchanged. Here, however, the direct use of the AMP-303 name and the matching study design make the hyaluronic-acid record far more probative than podcast shorthand. Osteopontin remains important to Amplifica's research foundation, but it should not be used as an automatic synonym for the company's clinical lead.⁷⁸

The first-in-human feasibility study enrolled 61 men between 18 and 45 with mild to moderate androgenetic alopecia. Thirty-two had experienced hair loss for three to five years, and 29 had experienced it for at least ten years. Each participant received AMP-303 on one frontotemporal side and saline on the other, creating a direct within-person comparison.⁵⁶

The conference abstract reports that AMP-303 was well tolerated and that adverse events were generally mild. In the recent-onset group, the abstract reports a mean 14.5% increase in non-vellus hair count among responders, peaking at day 60, with a difference from saline that remained statistically significant through five months. Amplifica separately reported that a statistically significant percentage of subjects crossed a 15% increase threshold at day 60 and a 10% threshold at day 150.⁵⁶

That is a real signal worth following. It is also an unusually easy result to overstate. The abstract emphasizes responders in one duration cohort rather than reporting a clean effect estimate for all 61 men. The public materials do not give the responder denominator, a complete result for the long-standing group, a result in women, confidence intervals for the headline changes, or follow-up beyond 150 days.⁵⁶

The phrase "one treatment cycle" also needs care. The patent's study example describes injections on three consecutive days, not one needle stick, and five months of observation is not yet a proven once-every-six-month commercial schedule. The appeal is still obvious: an occasional in-office course could be easier to live with than an indefinite daily drug. Larger repeat-dose trials have to show that promise survives contact with routine practice.⁷⁵

AMP-303 is the only Amplifica program with a public human dataset. It is not the whole bet. The company's current pipeline also names AMP-203/AMP-506 and AMP-601, while its research lineage reaches into two unusually interesting extracellular signals: osteopontin and SCUBE3.⁴⁸¹¹

In a 2023 interview, Plikus identified AMP-203 as an osteopontin-based compound in preclinical development. No comparable attributable source maps AMP-506 to a molecule or mechanism. Amplifica's current pipeline groups AMP-203 and AMP-506 visually, but that is not enough to assume that both are osteopontin analogs.⁹⁴

In the 2023 Nature paper, osteopontin was necessary and sufficient for the excessive hair growth seen around melanocytic nevi in mouse models. Human scalp follicles grafted into immunodeficient mice entered growth earlier after osteopontin treatment. That is powerful translational biology, but it is not a trial in living human scalps. The paper does not establish that an Amplifica osteopontin product will be safe, durable, or commercially practical.⁸

SCUBE3 comes from dermal papilla research. In experimental models, the protein acted as a mesenchymal niche signal and induced growth around transplanted human follicles in mice. UCI licensed the program to Amplifica, which identifies the compound as AMP-601 and describes it as preclinical. Again, the mechanism is compelling and the human efficacy evidence does not yet exist.¹⁰¹¹

Hair follicle stem cells do not regenerate a follicle alone. They sit inside a niche and respond to instructions from neighboring cells, especially dermal papilla fibroblasts. A landmark human study found that bald androgenetic-alopecia scalp retained a keratin-15-high stem-cell population but had fewer CD200-rich and CD34-positive progenitor cells. In plain language, the reserve was still present while the transition toward productive descendants was impaired.¹²

That finding makes Amplifica's signaling work attractive. Osteopontin can signal through CD44 on epithelial follicle cells, and SCUBE3 is produced by active dermal papilla cells in the experimental models. A therapy that restores a missing niche instruction could, in principle, help dormant follicles do more than briefly enter the cell cycle.⁸¹⁰

It does not prove that dermal papilla dysfunction is the only bottleneck, or that Pelage chose the wrong cell. PP405 is designed to inhibit the mitochondrial pyruvate carrier and shift hair follicle stem-cell metabolism toward activation. Foundational mouse research showed that Mpc1 deletion accelerated stem-cell activation and the hair cycle. That pathway is legitimate even if a complete regenerative response ultimately depends on signals from both sides of the niche.¹³¹⁴

The most interesting future may therefore be less tribal than the online argument. A treatment that changes stem-cell metabolism and another that improves niche signaling might turn out to address complementary bottlenecks. No published human study has tested that combination, and no current data lets anyone declare one cellular layer the only root cause of pattern hair loss.

Amplifica currently has the richer portfolio story. Pelage currently has the more advanced lead program and far more private capital. Those are different advantages, and neither is the same as proven hair growth in a large confirmatory trial.¹²⁰

Pelage completed a randomized, quadruple-masked, vehicle-controlled Phase 2a in 78 adults. Fifty-one participants entered the PP405 0.05% gel group and 27 entered the vehicle group for four weeks of once-daily use. Pelage submitted Version 14 of the results on July 14, 2026. ClinicalTrials.gov posted it on August 5 while National Library of Medicine quality-control review remained unfinished.¹⁴¹⁵

These are not FDA results. The registry marks PP405 as a study of an FDA-regulated drug, but Pelage supplied the data and NLM hosts the record. ClinicalTrials.gov says applicable-trial results must be posted within 30 days even when QC is incomplete, and that the sponsor remains responsible for the submission. Nothing in Version 14 is an FDA efficacy finding, review, or approval.¹⁵¹⁷

The randomized safety module reports at least one treatment-emergent adverse event in 22 of 51 PP405 participants, or 43.1%, and 10 of 27 vehicle participants, or 37.0%. It reports no serious event in the PP405 group, one upper-extremity fracture in the comparison group, and no deaths in either group. In the open-label extension, 8 of 20 participants reported an adverse event and none reported a serious event. Those numbers are directionally reassuring, but the small, uneven groups and unfinished QC do not establish safety equivalence.¹⁵

The posted pharmacokinetic table displays a mean of zero, with a range of zero to zero, at every reported time point. The SAP says values below the limit of quantification are assigned zero for summaries, so this pattern is consistent with concentrations below quantification. It does not establish literal zero exposure or prove why every result was entered as zero. The public unit is only "units on a scale." NLM flagged that unit as inconsistent and separately flagged the open-label time frame. Until Pelage corrects or explains the record, the posting does not permit a quantitative interpretation of systemic exposure.¹⁵¹⁶¹⁸

The most important result is the one that is missing. Version 14 publishes ten safety and tolerability outcomes plus two pharmacokinetic outcomes. It publishes no hair-density, hair-count, terminal-hair, photographic, or other hair-growth efficacy outcome. The February 2025 statistical analysis plan says there were no primary efficacy endpoints and no other secondary efficacy endpoints, then visibly blacks out the exploratory efficacy definitions and much of the efficacy analysis plan. Its unredacted introduction says Pelage was responsible for the pharmacodynamic analyses and that they would appear in a separate report. No such efficacy report appears in Version 14. An SAP is a methods document, so those redactions prove nondisclosure, not that the numerical result was good or bad.¹⁵¹⁶

Pelage's June 2025 release says the treatment was well tolerated, had no detected systemic absorption, and produced a fast hair-density signal. The number repeated in nearly every PP405 headline is that 31% of men in a higher-hair-loss subgroup achieved more than a 20% density increase at week 8, compared with none on vehicle.¹⁸

The new registry submission does not validate or contradict that 31% claim because it leaves hair growth out. Pelage still has not publicly supplied the subgroup size, complete randomized-population efficacy result, confidence intervals, a clear efficacy result for women, or a peer-reviewed full dataset. The company later said new terminal hairs emerged from previously inactive follicular units, but that too remains a company presentation claim rather than a result shown in Version 14.¹⁵¹⁸¹⁹

PP405 has not failed. Calling it a failure would ignore positive early evidence and a completed Phase 2a. Calling it a breakthrough already would ignore how much of the efficacy story remains outside the public result record. Pelage has now closed part of the safety-disclosure gap. It has not closed the hair-growth evidence gap. The fair verdict remains sharper than either extreme: Pelage has earned a late-stage test, not a victory lap.¹⁵¹⁸¹⁹

WHO Proposed INN List 135 gives the proposed name suvomipic to the same structure, formula, CAS number, and mitochondrial-pyruvate-carrier inhibitor already cataloged as JXL069. That settles one question. JXL069 is suvomipic. Our full suvomipic and PP405 evidence review walks through every link in that chain.²¹²²

The same WHO entry does not mention Pelage, PP405, the clinical trial, or the 0.05% gel. Pelage's trial registry does not list JXL069 or suvomipic as a synonym. The shared UCLA origin, MPC mechanism, patents, and timeline make the identity theory plausible. They do not provide the final direct statement that PP405 equals suvomipic.²¹¹⁴²³

This distinction became more important, not less important, once suvomipic appeared. A proposed generic name is a strong clue that a defined pharmaceutical substance is moving through a naming process. It is not a disclosure of every confidential sponsor code attached to that substance, and WHO explicitly says inclusion is not a recommendation for medical use.²¹

The supplied material argued that nearly a year of gray-market JXL069 use had produced no reports of hair growth. The public record is messier. Some users report no benefit or shedding. Others claim slight vellus changes, scattered terminalization, or visible improvement. One widely shared "one-year" update describes roughly twelve weeks of use followed by observation, not a year of continuous treatment.²⁴²⁵²⁶

None of those posts can establish efficacy. Products came from different vendors, identities and impurities were not independently authenticated across lots, vehicles varied, photo conditions were inconsistent, and many users combined other treatments. A molecule that is present in a bottle may still fail because of concentration, stability, scalp penetration, dose, adherence, or the rest of the formulation.²⁷

Even if Pelage eventually confirms that suvomipic is PP405's active drug substance, a third-party JXL069 solution would not become Pelage's clinical gel. Drug substance and finished drug product are different things. Manufacturing controls, vehicle, excipients, packaging, delivery, and chain of custody all sit between a chemical name and a tested medicine.²⁷

The honest interpretation is still uncomfortable for the hype. Months of inconsistent and largely unimpressive community evidence should stop anyone from assuming that a vendor bottle recreates PP405. It cannot be used to say Pelage failed, because it never established that Pelage's product was being tested in the first place.

If the question is which company has the more expansive scientific story today, our answer is Amplifica. It has a measurable early human AMP-303 signal, a clinical delivery model that may avoid daily adherence, multiple named programs, world-class follicle-biology research behind the platform, and now an oversubscribed round with Eli Lilly at the table.¹⁵⁴

If the question is which lead drug is further along, the answer is Pelage. PP405 has completed Phase 2a and Pelage raised $120 million to move toward late-stage development. Amplifica cannot claim clinical superiority from a smaller feasibility study, and scientific elegance has defeated plenty of biotechnology companies before.¹⁴²⁰

The reason Amplifica now deserves more of the spotlight is not that PP405 has been disproved. It is that Pelage's public narrative has been allowed to run far ahead of a still-incomplete efficacy dataset, while Amplifica has quietly assembled several distinct ways to influence the follicle and produced a human signal of its own. The $26 million raise makes that imbalance harder to ignore.¹¹⁸

Our ranking today is therefore specific, not absolute: Amplifica is the more compelling platform to watch; Pelage has the more mature clinical asset; neither has earned the word cure.

The next round of evidence matters more than another financing headline, podcast, patent theory, or carefully selected photograph. These are the disclosures that would move either company from promise toward proof.

• A complete AMP-303 datasetAmplifica should report the full intention-to-treat effect, responder denominators, both hair-loss-duration groups, uncertainty ranges, standardized images, and all safety events.
• A larger and more representative Amplifica trialWomen, older adults, repeat treatment cycles, vertex scalp, at least one year of follow-up, and a dose or schedule that resembles the intended product would make the result far more useful.
• A posted PP405 hair-growth analysisPelage has now posted safety and pharmacokinetics. It should add the complete randomized hair analysis, including all participants, women, subgroup sizes, confidence intervals, missing data, and protocol-defined efficacy methods.
• A registered late-stage PP405 studyA public protocol would reveal the intended population, duration, primary endpoint, comparator, sample size, and whether the impressive subgroup threshold survives as a prospective target.
• Clear program identitiesAmplifica can clarify how its osteopontin work maps to AMP-203/506, while Pelage can eventually settle whether suvomipic is PP405. Until then, code-name equations should remain labeled as unconfirmed.